Impact of the European Union on access to medicines in low- and middle-income countries
A scoping review

Perehudoff, K.; Durán, C.; Demchenko, I.; Mazzanti, V.; Parwani, P.; Suleman, F.; de Ruijter, A.

DOI
10.1016/j.lanepe.2021.100219

Publication date
2021

Document Version
Final published version

Published in
The Lancet Regional Health - Europe

License
CC BY-NC-ND

Link to publication

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
Series Review

Impact of the European Union on access to medicines in low- and middle-income countries: A scoping review

Katrina Perehudoffa,b,c,d,e,f,* , Carlos Durán,g , Ivan Demchenko,h , Valentina Mazzantif , Pramiti Parwani,a,b,c , Fatima Suleman,i,j , Anniek de Ruijtera,b,c

a Law Centre for Health & Life, Amsterdam Law School, University of Amsterdam, Nieuwe Achtergracht 166, 1018 WV Amsterdam, Netherlands
b Amsterdam Institute for Global Health and Development, Pauwheulweg 25, 1105 BP Amsterdam, Netherlands
c Amsterdam Centre for European Law and Governance, Amsterdam Law School, University of Amsterdam, Nieuwe Achtergracht 166, 1018 WV Amsterdam, Netherlands
d WHO Collaborating Centre for Governance, Accountability, and Transparency in the Pharmaceutical Sector, University of Toronto, Canada
e Medicines Law & Policy, Amsterdam, the Netherlands
f Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Campus Westville, Durban, 4041, South Africa
g Department of Forensic Medicine and Medical Law, Bogomolets National Medical University, st. Mechnikova, 5, Kyiv, 01133, Ukraine
h Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, Netherlands
i Department of Public Health & Primary Care, Ghent University, Ghent, Belgium
j WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, University of KwaZulu-Natal, Campus Westville, Durban, 4041, South Africa

A R T I C L E  I N F O

Article History:
Received 20 June 2021
Revised 11 August 2021
Accepted 24 August 2021
Available online xxx

S U M M A R Y

This Scoping Review synthesises evidence of the impacts of European Union (EU) law, regulation, and policy on access to medicines in non-EU low- and middle-income countries (LMICs), and the mechanisms and nature of those impacts. We searched eight scholarly databases and grey literature published between 1995-2021 in four languages. The EU exerts global influence on pharmaceuticals in LMICs in three ways: explicit agreements between EU-LMICs (ex. accession, trade, and economic agreements); LMICs’ reliance on EU internal regulation, standards, or methods (ex. market authorisation); ‘soft’ forms of EU influence (ex. research funding, capacity building). This study illustrates that EU policy makers adopt measures with the potential to influence medicines in LMICs despite limited evidence of their positive and/or negative impact(s). The EU’s fragmented internal and external actions in fields related to pharmaceuticals reveal the need for principles for global equitable access to medicines to guide EU policy.

© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

R E S U M E N

Esta revisión exploratoria sintetiza la evidencia disponible sobre el impacto que ejercen las leyes, las políticas y las regulaciones de la Unión Europea (UE) sobre el acceso a los medicamentos en países de bajo y mediano ingreso (PBMI) que no pertenecen a la UE. La búsqueda se realizó en ocho bases de datos académicas, incluyendo literatura gris. Se incluyeron publicaciones en cuatro idiomas entre 1995 y 2021. Como resultado principal se encontró que la UE ejerce su influencia sobre los productos farmacéuticos en los PBMI a través de tres mecanismos principales: i) acuerdos explícitos entre la UE y los PBMI, por ejemplo, acuerdos de ascensión a la UE o tratados comerciales, ii) utilización de la normativa, estándares o métodos de la UE por parte de los PBMI (reliance) para, por ejemplo, autorizar el ingreso de nuevos medicamentos a partir de la autorización previa por parte de la UE y, iii) formas blandas de influencia de la UE, por ejemplo, a través de financiación a la investigación o el desarrollo de capacidades locales. Esta revisión revela que los tomadores de decisión de la UE adoptan medidas que, a pesar de la escasa evidencia que sustenta su impacto, positivo o negativo, tienen el potencial de influir en el acceso a los medicamentos de los PBMI. El acionar fragmentado de la UE respecto a los productos farmacéuticos, tanto a nivel interno como externo, son una clara muestra


* Corresponding author: Katrina Perehudoff, Law Centre for Health & Life, University of Amsterdam, Nieuwe Achtergracht 166, 1018 WV Amsterdam, Netherlands. Telephone: +32 493 86 88 26
E-mail address: katrina.perehudoff@gmail.com (K. Perehudoff).

https://doi.org/10.1016/j.lanepe.2021.100219
2666-7762/© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
de la necesidad de crear principios que guíen las políticas de la UE frente al acceso equitativo a los medicamentos a nivel global.

© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

**A B S T R A C T**

This comprehensive investigation covers data on the global regulatory influence of the European Union (EU) on access to medicines in low- and middle-income countries (LMICs) due to unaffordable medicines prices, medicines shortages, and insufficient health coverage [2,3]. These challenges are compounded by insufficient research and drug development for neglected, poverty-related, and vaccine-preventable diseases [2]. These realities persist despite UN Resolutions and political commitments to achieve universal access to essential medicines, which is an integral part of the right to health enshrined in the International Convention on Social, Economic, and Cultural Rights, and the Sustainable Development Goal 3 for health [4,5].

The European Union (EU) has the potential to significantly influence access to medicines in non-EU LMICs (hereafter LMICs). The EU is a key pharmaceutical exporter to LMICs, a trade hub for medicines in transit, and a major global health donor for drug development and procurement by international agencies [6,7]. The 2010 Council Conclusions on the EU’s Role in Global Health were adopted following earlier criticisms of the EU’s incoherent trade and aid agendas for access to medicines [8,9]. The Council Conclusions established that EU action on health outside its borders should be guided by solidarity and ensure that the main components of health systems - including access to medicines - are effective enough to deliver universal coverage of basic quality care, through a holistic and rights-based approach [10]. However, the policy influence of the Global Health Council Conclusions has remained limited, and its impact on access to medicines outside the EU is unknown [11,12].

The pharmaceutical markets of the EU and many LMICs are intertwined, and in some ways, interdependent. On one hand, the EU’s internal pharmaceutical policy appears to impact medicines policy and access in LMICs [13,14]. For example, the EU’s large-scale Covid-19 vaccine procurement and export bans stunted the available global supply, disproportionately impairing access for people in LMICs. On the other hand, LMICs are increasingly instrumental to guaranteeing the EU’s pharmaceutical supply, e.g. as clinical testing sites for new medicines marketed in the EU, and a source of raw materials [15].

The precise mechanisms and impacts of the EU’s external and internal action on LMICs’ access to medicines have not been investigated. Regulatory theories and international relations literature point to several mechanisms through which the EU could influence commodities in non-EU markets [16]. However, these mechanisms have not been explored in relation to pharmaceuticals, which, compared to other commodities, are a highly regulated market with many intermediaries. Empirical studies of pharmaceutical policy and regulation in LMICs, and legal analyses, often do not distinguish between the effects of EU action, and the related activities of other stringent regulatory authorities, individual EU member states, and/or the World Health Organization (WHO) [15,17,18]. A holistic understanding of how EU action influences pharmaceutical access in LMICs, as well as the gaps in that knowledge, will be a first step towards a more resilient EU approach for global health in all policies.

To address this need we conducted a Scoping Review to synthesise what is known about the impacts of EU law, regulation, and policy (hereafter called ‘EU action’) on access to medicines in LMICs, and the mechanisms and nature of those impacts. A more complete understanding of the external impacts of EU action on pharmaceuticals can support resilient global medicines supply chains and health systems, sustained disease eradication, poverty alleviation, and sustainable development, and expand the pandemic preparedness and response efforts [2,19–21].

**2. Methods**

A scoping review was selected because evidence in this field is fragmented across disciplines. This review concerns access to medicines, which we define broadly as the development, marketing, and use of medicinal products at all stages of the product lifecycle. Medicines are understood as medicinal products defined by the European Medicines Agency (EMA) as ‘A substance or combination of substances that is intended to treat, prevent or diagnose a disease, or to restore, correct or modify physiological functions by exerting a pharmacological, immunological or metabolic action.’ [22]

**2.1. Search strategy and selection criteria**

According to our protocol (unpublished, see Supplementary Annex), designed in line with the PRISMA-Sr guidelines [23], we searched eight databases (Ovid Medline, Scopus, Web of Science, Epistemonikos, HeinOnline, LilACS, E-library, Nauchny Arhiv) and replica literature. We included documents on English, Spanish, and Russian, and published between 1995-2021, which were classified as either EU policies or related activities. The detailed search strategy is available in the Supplementary Annex.
Following a period of calibration among the authors, search results were screened by KP, CD, ID and PP according to the inclusion criteria that the publication concerned an EU law, regulation, or policy in relation to access to medicines in LMICs generally or in specific LMICs defined by the World Bank. Access to medicines was broadly understood as the development, marketing/provision, and/or use of pharmaceuticals. Relevant publications underwent full text screening for eligibility by KP (English), PP (English), CD (Spanish/Portuguese), and ID (Russian). Ineligible publications lacked a reference to EU action, to medicines access in LMICs, or to a connection of these two concepts; were in a language other than English, Spanish, Portuguese, or Russian; or did not have a full text. The results were validated in a cross-over arrangement by CD (English), ID (English), and VM (English/Spanish), who independently checked the full text of 25% of the publications. Discrepancies were discussed and resolved.

A data abstraction template was developed based on a structure-outcome-impact framework and tested by KP. The template included generic information (citation, article type, funding source, authors’ affiliations by sector) and study-specific data for original and review articles (LMIC(s) setting; study design; data sources; EU law, regulation or policy; outcome and impact of EU action). Data were extracted by KP (English), CD (Spanish), and ID (Russian). Abstraction was validated for 24% of the included English documents (including all original scientific articles) by CD, ID, and PP. Evidence was classified through iterative discussion among co-authors according to a framework of EU global regulatory influence (described elsewhere) [16]. A quality appraisal was not conducted because the included publications were too heterogeneous in scope and design. Many publications reviewed claimed (untested) associations (rather than causation) between EU action and pharmaceuticals in LMICs. The analysis below includes the most relevant evidence from this review. The Supplementary Annex provides a list of all included publications.

2.2. Role of the funding source

The funders had no role in the impetus, design, conduct, analysis or writing of this review. The corresponding author had full access to all data and final responsibility for the decision to submit this review for publication.

3. Results

The initial search produced 3954 documents, which, after removing 586 duplicates, resulted in 3368 documents that underwent title/abstract screening. See Figure 1. Of these, 3092 documents were excluded, leaving 276 documents that underwent full-text review. Of these, 167 documents were excluded because there was no link between an EU action and LMICs (n=92), no EU action (n=34), no full text (n=27), pharmaceuticals for human use were not investigated (n=8), or the study was in a language besides English, Spanish, Portuguese, or Russian (n=6). 109 publications were included in the review. Table 1 shows the characteristics of the included publications.

3.1. Current knowledge on the impact of EU action on access to medicines in LMICs

This section synthesizes the evidence of three mechanisms through which the EU influences access to medicines in LMICs. See Table 2.

3.1.1. Explicit agreements between EU-LMICs

3.1.1.1. EU enlargement. Enlarging the EU to include its neighbouring countries is a means to motivate potential candidate and candidate countries (mostly LMICs in the European region) to align

![Fig. 1. Document selection process.](image-url)
Table 2

<table>
<thead>
<tr>
<th>Mechanisms of EU influence</th>
<th>Area of EU law, regulation, or policy</th>
<th>Nature of impacts in LMICs</th>
<th>Illustrative publications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Explicit agreements between EU-LMICs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EU enlargement</td>
<td>Candidate EU member states harmonize local standards with EU regulatory data protection</td>
<td>At the time of accession about 1/3 of market approvals in the candidate member state were granted through the EU recognition procedure, and 2/3 through national authorization</td>
<td>[25]</td>
</tr>
<tr>
<td></td>
<td>Candidate EU member state recognises on its local market approvals granted through EU procedures</td>
<td>After accession the majority of new market approvals in the new EU member state were granted through EU procedures</td>
<td>[26]</td>
</tr>
<tr>
<td><strong>EU-LMIC trade agreements and economic partnerships</strong></td>
<td>LMIC trade partners adopt longer periods of regulatory data protection and patent extensions</td>
<td>Lost savings on pharmaceuticals</td>
<td>[29]</td>
</tr>
<tr>
<td></td>
<td>LMIC trade partners remove tariffs on EU pharmaceutical imports</td>
<td>Potential for reduced availability and market shares of generic medicines launched on LMIC markets post-EU trade agreement</td>
<td></td>
</tr>
<tr>
<td><strong>EU internal market action affects LMICs</strong></td>
<td>Waiver for EU patent term extensions allow generic and biosimilar medicines to be produced in the EU for export (patent term extensions are also called supplementary protection certificates)</td>
<td>List prices of medicines registered under this system are not significantly lower than for products supplied outside of this regulation nor the same products sold in other countries</td>
<td>[32]</td>
</tr>
<tr>
<td></td>
<td>Measures to prevent the re-importation into the EU of low-priced medicines for HIV/AIDS, TB, malaria intended for LMICs</td>
<td>Detention of shipments of generic medicines in transit through the EU and destined for LMICs. Shipments are delayed reaching LMICs or are returned to their country of origin.</td>
<td>[35]</td>
</tr>
<tr>
<td></td>
<td>EU customs enforcement measures</td>
<td>EU recognizes or abbreviates the EC’s market authorization decisions for new chemical entities on local markets</td>
<td>[30]</td>
</tr>
<tr>
<td><strong>EU internal regulation influences actors in LMICs to adhere to EU standards</strong></td>
<td>In order to access the EU market, medicines manufacturers and their affiliates must declare to have followed good clinical practices and ethical standards during clinical development</td>
<td>May result in expedited regulatory approval of essential medicines in LMICs.</td>
<td>[41]</td>
</tr>
<tr>
<td></td>
<td>LMIC regulatory reliance and mirroring of EU internal market regulation</td>
<td>May reduce LMICs’ autonomy over their regulatory decisions, which is problematic when the EU’s decisions being mirrored have a weak evidence base.</td>
<td>[43]</td>
</tr>
<tr>
<td><strong>‘Soft’ forms of EU influence on LMICs</strong></td>
<td>Through the EU-Medicines4all (Article 58 procedure the EMA assesses and provides scientific opinions of new medicines solely intended for third countries (usually LMICs))</td>
<td>Six medicines with positive EMA opinions were granted 138 regulatory approvals in 90 countries.</td>
<td>[45]</td>
</tr>
<tr>
<td></td>
<td>EU funding for research and clinical development of pharmaceuticals for neglected infectious diseases (e.g., EDCTP)</td>
<td>Development of new (candidate) medical products</td>
<td>[60]</td>
</tr>
<tr>
<td></td>
<td>EU coordinates development funding for harmonizing LMICs’ pharmaceutical regulation and establishing pooled procurement</td>
<td></td>
<td>[66]</td>
</tr>
<tr>
<td></td>
<td>EU-funded humanitarian aid organizations must respect internationally recognized principles of good practice for medical products for procuring medicines</td>
<td></td>
<td>[68]</td>
</tr>
</tbody>
</table>

aspects of their internal market policies related to medicines with those of the EU, which is a condition for EU membership. As part of this process EU candidate and potential candidate countries may receive technical and other support from the European Commission (EC, the executive branch of the EU) in the field of pharmaceuticals [24]. Accession countries need to reform their legislation to adopt regulatory data protection of pharmaceuticals conform with EU levels, which is higher than the minimum required in global trade law (Agreement on Trade Related Aspects of Intellectual Property, TRIPS Agreement). Regulatory data protection can delay generic competition, resulting in lost savings on medicines purchases. Survival analysis demonstrates that EU applicants (mostly LMICs) are 7.47 times more likely to adopt higher (TRIPS+) standards of regulatory data protection than non-applicant countries [25]. EU accession was the primary motivation for these regulatory data protection reforms. The process of EU accession has been called the ‘coercive diffusion’ of EU norms because LMICs applicants lacked other national interests in stronger data protection standards and resisted and delayed their adoption [25].

Prior to accession candidate EU Member States receive technical support and capacity building in order to harmonise their drug regulation standards with those of the EU. In addition, in the case of Croatia, it was permitted to exchange confidential and safety information with EU regulators and to adopt a simplified recognition procedure for EU market approvals previously granted [26,27]. These measures are described as improving access to medicines in Croatia by increasing the number of medicinal products with market...
approval in the country "by nearly one-third when Croatia acceded to
the EU"; however, it was unclear whether these products were avail-
able on the Croatian market [26]. In the four years after accession an
average of 88% of 'recently licensed medicinal products in Croatia
were approved through an EU (not a Croatian) procedure [26]. The
precise role of the EU accession agreement was not robustly tested.

3.1.1.2. EU trade agreements and economic partnerships. Bilateral and
multilateral trade agreements and economic partnerships between
the EU and LMICs often require trade partners seeking access to the
EU market to adopt the same or similar standards into the EU in their
domestic law. The IP standards and tariffs in these agreements could
affect LMIC trade partners’ capacity to trade pharmaceuticals globally
and to regulate prices domestically. For example, the EC negotiated
five years of regulatory data protection and five-year patent term
extensions in the 2013 EU-Peru/Colombia free trade agreement (FTA,
which Ecuador joined in 2017) [28]. After concluding the FTA these
measures were introduced into LMICs’ domestic law despite exceed-
ing the minimum levels of protection required by the TRIPS Agree-
ment.

No peer-reviewed studies assessed the impact of EU trade agree-
ments on LMICs’ medicines supply. IQVIA, a company collecting data
on pharmaceuticals, reported that regulatory data protection and
patent extensions in the EU-Peru/Colombia FTA caused lost savings
on retail pharmaceuticals in Peru and Colombia (between 2013-2018),
and Ecuador (2017-2018) [29]. A pre-/post-analysis by IQVIA in Ecuador
found a moderate reduction the number and proportion of
generic manufacturers marketing medicines in Ecuador, and a sub-
stantial reduction in the market shares of generic medicines for
hypertension [29]. This means that the reduced availability and suc-
cess of generic medicines launched in Ecuador after 2017 may be
attributable to the FTA; it was not reported whether the stronger
data protection standards contributed to these pre/post changes.

Reduced tariffs on pharmaceuticals (among other products) are
commonly pursued in trade agreements. An ex-ante economic anal-
ysis found the reduced tariffs proposed in the EU-Vietnam Trade
Agreement (EVFTA) would lead to increases in EU medicines imports
into Vietnam, particularly of analgesics, antipyretics, anaesthetics, anti-
biotics and antiretrovirals for HIV/AIDS, cancer, antiparkinsonians,
and cardiovascular medicines [7]. As a result, EU medicines imports
would be ‘cheaper’ than before the EVFTA, leading them to compete
with domestic manufacturers and imports from other low-priced
Asian markets (i.e. India, China, Thailand) where Vietnam also has
trade agreements [7]. Reduced tariffs on pharmaceuticals would ulti-
mately yield minor welfare benefits for Vietnam, and possible nega-
tive effects for the country’s integration in the Asian region [7].

Another IP standard requested by the EC and adopted in EU-LMIC
trade agreements is customs enforcement measures, for which no
evidence of impact was retrieved [30].

3.1.2. EU internal market action affects LMICs

3.1.2.1. Medicines exports and shipments to LMICs. A major objective
of the EU is to regulate the smooth functioning of its single market
consisting of 27 EU Member States, Iceland, Liechtenstein, and Nor-
way. The EU achieves this through its internal decisions in a range of
policy areas that can affect the export and/or transit of pharmaceuti-
cals through the EU to LMICs.

One policy area is the adoption of EU patent term extensions
(called supplementary protection certificates, SPCs) that, when first
introduced, prevented EU generics and biosimilar producers from
manufacturing medicines for export while they were still protected
by the SPC in the EU. In 2019 the EU introduced a waiver allowing EU
generics and biosimilar producers to manufacture medicines for
export [31]. No medicinal product has been produced for export
under this waiver system [32].

Another policy area is EU regulation to prevent trade diversion
(re-importation into the EU) of lower-priced medicines for HIV/AIDS,
TB, and malaria medicines destined for LMICs [33]. In 2003, the EU
introduced a database and visual recognition for registered EU
exports to 76 LMICs to encourage manufacturers to supply to LMICs
at reduced prices and large quantities without fear of trade diversion
[34]. No peer-reviewed studies investigated the impact of this regula-
tion. An evaluation commissioned by the EC found that from 2003-
2013 only one company registered nine antiretrovirals to treat HIV/
AIDS under the regulation [34,35]. Those medicines were supplied at
higher initial volumes in the 76 countries (2005-2008) than before
being covered by the regulation [35]. The medicines list prices were
not significantly lower than products supplied outside of this regula-
tion nor compared to these products sold in other countries [35].

A third area is the enforcement of the EU’s IP standards on ship-
ments of generic medicines transiting through the EU and destined
for LMICs. Although the shipments are not protected by IP in their
countries of manufacture and destination (often LMICs), they may be
detained when passing through the EU if they are suspected of
infringing on IP rights protected in the EU [29,36,37]. The EU’s IP
enforcement measures aim to protect against the illegitimate trade in
counterfeit or pirated goods, and risks to EU consumer health and
safety; these rules apply to products both imported into and transit-
ning through the EU. Numerous shipments of legitimate generics tran-
siting to LMICs were detained at EU borders between 2008-2010;
however, no peer-reviewed impact analysis was retrieved [29,37].
One example is of a shipment of losartan, equivalent to one-month
hypertension treatment for 300,000 Brazilian patients, that was
detained by the Dutch customs authorities for 36 days. After being
released to return to India, the shipment never reached Brazil
[37,38]. In 2013 the EU adopted legislation intending to safeguard
against such seizures, however, subsequent EU regulation (adopted
in 2015 and 2017) could allow for detentions of medicines in transit
suspected of infringing on protected trademarks in the EU. No studies
report the impact of these EU laws.

3.1.2.2. Actors adhere to EU standards in LMICs. The EU regulates the
safety, efficacy, and quality of pharmaceuticals on the internal mar-
et. In doing so it imposes certain obligations on manufacturers com-
mercialising their medicines in the EU. Those obligations require
manufacturers and their affiliates (involved in researching, produc-
ning, or marketing medicines in the EU) to adhere to certain EU norms,
even if these entities or their activities are located outside the EU. In
this way, norms codified in EU law for good clinical practices (includ-
ing pre-marketing safety), good manufacturing practices, and post-
marketing pharmacovigilance and reporting may be externalised and
respected by manufacturers active in LMICs [39]. For example, medi-
cines manufacturers seeking access to the EU market must declare
that all clinical testing adhered to the EU’s ethical standards and
good clinical practice, including at testing sites outside the EU (i.e. in
LMICs) [40,41]. Commentators from the pharmaceutical industry sug-
gest companies are key intermediaries with the experience, compe-
tence, and obligations from highly regulated markets, as well as the
resources, to perform pre- and post-market safety reporting well in
LMICs [42]. No peer-reviewed study examined the impact of such EU
regulation on company behaviour in LMICs, nor on the decisions of
LMIC regulators.

3.1.2.3. LMIC regulatory reliance and mirroring of EU internal market
regulation. LMIC authorities rely on, mirror, and/or adapt EU deci-
sions and technical standards for local regulatory approval, and trans-
pose EU methods and tools for monitoring medicines use in LMIC
markets. Regulatory reliance on foreign decisions, standards, and
methods occurs on a spectrum ranging from inspiration for local
adaptation to direct local recognition without further adjustments
[43,44].
Regulatory reliance by LMICs is most frequently reported in relation to the EC's market authorisation decisions, notably in non-EU Eastern European countries and Latin America [43,46–47]. Thirteen Latin American regulatory bodies responsible for 34 countries have adopted domestic legislation that recognises or abbreviates the EC's market authorisation decisions (among other reference regulators) for new chemical entities [43]. Twelve of these regulators also recognise the EC's market approval without an additional local assessment [43]. Latin American regulators rely on the EC's decisions about cancer medicines based on poorly performed clinical trials using surrogate endpoints [43]. Between 2009–2013 six Latin American regulators approved more than 70% of the 17 EC-authorised cancer medicines that were lacking evidence of overall survival (primary endpoint) [45]. From 2014–2016 Latin American regulators approved between 62% (Panama) to 85% (Brazil) of the 13 EC-authorised cancer medicines despite the fact that no clinical trial was submitted in support of the decision, or all submitted trials were judged to be at a high risk of bias [45].

Regulatory reliance was reported in other areas of pharmaceutical policy. LMIC regulators reportedly use an iteration of the EMA guidelines for evaluating biosimilar products as a model for standards adopted in China [48], Malaysia [48], South Africa [49], and Ukraine [49,50]. LMIC regulators may also draw from the EMA's post-marketing updates to market authorisations. For example, LMIC regulators suspended rosiglitazone-containing anti-diabetics from their markets after the EMA announced the same measure on September 23, 2010 due to safety concerns [51]. A causal link between EMA's and LMICs' decisions were not evaluated. Other LMIC authorities have adopted the definitions, methods, and tools from the European Centre for Disease Prevention and Control or Eurobarometer to monitor local antibiotic use and generate cross-national comparisons [52,53]. National health ministries adapted these EU tools to generate data supporting biotic use and generate cross-national comparisons [52,53].

Reliance on EU regulation appears to be the decision of LMIC regulators and/or legislators. Their decisions may be modulated by the EU's status as one of the few 'stringent regulatory authorities' worldwide, and as such a potential model for other regulators. Additionally, the regulations, policies, and actions of other 'stringent regulatory authorities' (e.g., United States Food and Drug Administration) may impact on LMICs' decisions to rely on the EC/EMA instead of or in addition to other regulators [43,54]. LMICs' market size may also modulate their reliance on the EC/EMA. One trend suggests that in order to assess the bioequivalence of local generics regulators, small and some mid-sized markets (e.g., South Africa) accept studies with foreign comparators that have been approved in founding members of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (e.g., EU), whereas large-market regulators (e.g., Brazil, Mexico) do not [55].

Manufacturers opting to first seek EC approval for their product (before seeking approval in a LMIC) may also do so to enjoy the accompanying advantages, such as gaining access to the EU market and benefiting from EU incentives for orphan medicines [56,57]. EU regulatory incentives for designated orphan medicines include advice on clinical development, expedited evaluation, and, if authorised, market exclusivity blocking competitors on the EU market for ten years [57]. Several medicines that were primarily intended for LMICs have received an EU orphan designation and subsequent EU market authorisation, such as (non-exhaustive list): dihydroartemisinin / piperaquine phosphate (malaria) [56,57], a TB vaccine [58], paromomycin (visceral leishmaniasis) [55,58] (the product developers requested to withdraw the EC orphan status after the designation was granted) [55]. It is unclear what role, if any, the EU orphan designation played in follow-on impacts in LMICs, such as market approval.

3.1.3. 'Soft' forms of EU influence on LMICs: technical assistance, resource mobilisation, and 'capacity building'

The notion of 'soft' forms of EU influence is inspired by the description of the EC's 2010 Globalisation and Health conference and its framing around EU policies as a means of "spreading European influence by 'soft' means of discussion, exchange and funding, rather than 'hard' means of trade and war" [59].

The EU provides technical assistance, mobilises global financing, and engages in capacity building on pharmaceutical issues towards LMICs in different policy areas. Through EU-Medicines4all (also called the Article 58 procedure) the EMA provides scientific opinions on medicines intended for use in third countries (usually LMICs) in collaboration with WHO. The EMA's assessment involves WHO and LMIC regulators as observers; it does not lead to EU market authorisation [54]. LMIC regulators may rely on EMA opinions alone or in combination with decisions by WHO or other regulators when assessing the same medicine [17]. Between 2004–2019 EMA issued 10 positive opinions for new medicines, of which four were withdrawn by the opinion holder (company). For the remaining six medicines with a positive opinion, 138 regulatory approvals were granted in 90 countries [60]. The exact role of EMA's positive opinion in the LMIC approval processes was not investigated.

The EC's Directorate General (DG) for Research and Innovation financially supports the development and testing of pharmaceuticals and tools to improve the use of medicines primarily intended for priority needs in LMICs [60]. The European Commission's Framework Programmes (FP) 4 to FP6 (1997–2006) funded research on neglected infectious diseases (including HIV/AIDS, TB, and malaria) including vaccine research (FP5-FP7) leading to the development of several candidates for Buruli ulcer, leishmaniasis, and TB [62,63,65]. Within the EC's FP7s is the 'European and Developing Countries Clinical Trials Partnership' (EDCTP), an EC initiative that catalysed global contributions towards the clinical development of priority HIV/AIDS, TB, and malaria medicines for Sub-Saharan Africa [63,64]. The EDCTP leverages EC funding to pool contributions from EU Member States and non-EU governments, industry, and philanthropies for the clinical development of medicines and capacity building of Sub-Saharan partners on ethical review standards and the conduct of clinical trials [66]. Every Euro invested by the EC in the EDCTP attracted an additional 1.50 Euro (2003–2011) [65] and 2.60 Euro (projected 2014–2020) from other contributors [63].

DG International Partnerships coordinates the EU's development policy, including the European Development Fund (EDF) that mobilises funding directly from EU Member States and is managed outside of the EU budget. EDF supports collaboration between the EU, the African, Caribbean, and Pacific States (ACP), and WHO for harmonising pharmaceutical regulation and establishing pooled procurement aligned with WHO regulatory standards [67,68].

DG European Civil Protection and Humanitarian Aid Operations requires entities providing aid (often in LMICs) financed by the EU to respect internationally recognised principles of good practice for medical products, particularly for pharmaceutical procurement (ex. good manufacturing, storage, laboratory, clinical and distribution practices; WHO's quality assurance standards) [18]. In this way the EC promotes the diffusion of pharmaceutical standards that include but are not limited to the EU's own standards.

No peer-reviewed studies examined the follow-on impacts of the EC's direct investments in coordination activities on, for example, LMICs' pharmaceutical policy reform, or the approval, availability, or use of medicines in LMICs that were developed or provided through the above programs.
4. Discussion

Our review coalesces evidence from different disciplines to illustrate three mechanisms through which EU action impacts on medicines in LMICs. One, the EU’s external, treaty-based actions establish explicit agreements with LMICs and can affect their pharmaceutical trade, sales, and use. Two, EU’s internal market regulation, standards, and methods are used as bases, models or sources of inspiration for pharmaceutical governance in LMICs. Three, ‘soft’ forms of EU influence manifest through the EU’s technical assistance, its mobilisation of research and development (aid) funding, and its ‘capacity building’ activities towards LMIC actors in the field of pharmaceuticals. For each mechanism several examples from pharmaceutical policy were retrieved. The impacts of EU action ranged from the development of new medicines primarily for LMICs, to changes in the availability of generics and on medicines spending in LMICs, and the potential for a more efficient yet less autonomous local market approval process. Most evidence of impact was not peer reviewed. Overall, this study points to the question of how to support resilient global pathways for drug development and regulation that generate efficiencies while still being responsible and accountable to the local public interest.

Although the EU can influence access to medicines and the sustainability and resilience of health systems in LMICs, peer-reviewed evidence of the EU’s impact is limited in scope, volume, and scientific rigour [69]. This may be due to a lag in the international diffusion of EU action and/or delays in local implementation, which means the follow-on effects manifest in LMICs years or decades later [17]. Another reason may be the publication bias towards studies in LMICs. Additionally, some areas of EU policy (with the potential to impact LMICs’ pharmaceutical policies) were scarcely addressed in the literature, such as the EU’s external aid agenda, the EU network for health technology assessment (which includes one LMIC, Ukraine [70]), and the EU joint Covid-19 vaccine procurements. Despite numerous claims made in the literature, there is little investigation of the full range of both potential positive and negative impacts for LMICs’ pharmaceuticals. Moreover, the literature heavily focuses on impacts in the field of HIV/AIDS, TB, malaria, and other infectious diseases while neglecting impacts on access to new medicines for non-communicable diseases (e.g., cancer, diabetes, and cardiovascular disease) and rare diseases, which are often high-priced in LMICs. Finally, some study designs did not report the EU’s role independent of EU Member States, comparable global powers (e.g., US) and/or international bodies (e.g., WHO, World Trade Organization (WTO)) that promote similar policy measures [17,71].

This research has important implications for EU law and policymaking. This study illustrates that EU policy makers adopt measures with the potential to influence medicines in LMICs despite limited evidence of their impact. For example, this review reveals that the EU’s market authorisations have the potential to influence regulatory decisions affecting at least 380 million people in Latin America (among other world regions). This review also demonstrates the key role of EMA in influencing LMIC pharmaceutical policy, both intentionally through the EUMeds4All/Article 58 procedure, and unintentionally when LMICs rely on EMA’s regulatory actions. LMICs appear to rely on the EU’s regulatory decisions (instead of WHO recommendations, for example) because companies marketing a new medicine may first seek the approval of a ‘stringent regulatory authority’ such as the EU, which serves as a basis for WHO pre-qualification (PQP) [17], and because some LMIC regulators and WHO PQP require a foreign comparator for generic and/or biosimilar products [55].

Notably, the impacts of other EC policy responses for the development and deployment of pharmaceuticals needed globally in the Covid-19 pandemic were not examined in the literature. In practice, these measures appeared to take an insular, EU-centric approach without considering the external-EU policy impacts. For example, the EC’s advanced purchase agreements for Covid-19 vaccines, and the EC’s plans to upscale vaccine production (foreseen in the European Health Emergency Preparedness and Response Authority Incubator) do not address how these EU actions could support greater vaccine production globally, such as through IP licensing and technology transfer [72]. One step in this direction would be for the EC to require its funding recipients to share the resulting IP, know-how and knowledge for Covid-19 medical products with the WHO Covid-19 Technology Access Pool.

The fragmentation of EU internal and external actions in fields related to pharmaceuticals illustrate the need for a series of principles for global equitable access to medicines to guide EU policy. These principles should be developed based on EU legal principles and values, and the Global Health Council Conclusions. Moreover, the EU’s impact assessments (prospective and retrospective) of its own legal and policy interventions should consider unintended impacts on pharmaceuticals in third countries, which requires the development and testing of new methodologies.

Further research is needed to categorically unpack the full spectrum of EU influence on pharmaceuticals in LMICs, and inform policy makers in Europe and abroad. Transdisciplinary research approaches should combine theories and methods from different disciplines to elucidate the normative role of the EU in global access to medicines, the power relations between the EU and LMICs, and the intentional and unintentional impacts of EU action on pharmaceuticals, and how these impacts can be compared, monitored, and optimised. The potential differential effects of EU action in LMICs should be disaggregated by their level of economic development, geographic scope, and/or EU candidate/partnership status. Priority policy areas for future study are those in the EU’s 2021–2027 Pharmaceutical Strategy [21]. Robust empirical designs, such as longitudinal and/or quasi-experimental designs, should be used to permit conclusions about causality. A range of dependent variables should be applied to capture the intermediate outcomes and end impacts on LMICs’ legal, policy and institutional structures (e.g., regulatory reform, medicines litigation), health systems processes (e.g., market launch, and the selection, availability, pricing, and affordability of medicines), and individual and population health outcomes. Establishing advisory panels in LMICs can help identify and capture meaningful indicators for local populations. Future research should consider intermediaries’ (e.g., multinational and domestic pharmaceutical manufacturers, and third-party procurers supported by EU funding) practices for product development, marketing, and/or distribution, and how these practices modulate the dissemination and impact of EU action in LMICs [17].

This Scoping Review coalesces literature from a range of policy areas in four UN languages and across the interrelated, yet often siloed, disciplines of public health policy, international relations, and EU law. It synthesises the current knowledge about the mechanisms and impact of EU action on pharmaceuticals in LMICs through the lens of EU global regulatory influence. Our snowball reference search cross-referenced many publications that were already retrieved through our database search, which suggests our database search is complete. Nevertheless, this study does not capture the EC’s early international cooperation actions about pharmaceuticals (ongoing since 1983), and may have missed literature in other languages. The selection of Russian articles was not validated by a second researcher. This study does not investigate the impacts of individual or groups of EU Member States, the EU’s global political activities within multilateral bodies (ex. WHO, WTO), nor the EU’s financial support of international initiatives for access to medicines (ex. Global Fund, Covax).

Contributors

KP and AdR conceived of the study. KP designed the protocol and analysis, that was reviewed by all authors. KP, CD, and ID conducted the search. KP, CD, ID, VM, and PP reviewed the literature. KP and CD
conducted the analysis. KP drafted the manuscript that all authors revised. KP, CD, ID, FS and ADR participated in the interpretation. All authors critically revised the manuscript for intellectual content.

Declaration of interests

ADR and PP report grants from European Commission’s Horizon 2020 programme (Grant no. 874653); ADR reports a grant from Dutch Research Council; KP reports grants from Unitaid, grants from Flemish Interuniversity Council (VLIR-UOS) and the Belgian Directorate-General for Development Cooperation during the conduct of the study. ID is a private attorney. His clients (including pharmaceutical companies) have no direct interest in the topic of this article. CD, VM, and FS have nothing to disclose.

The funders had no role in the impetus, design, conduct, analysis or writing of this review. The corresponding author had full access to all data and the final responsibility for the decision to submit this review for publication.

Acknowledgments

The authors acknowledge the helpful feedback from the anonymous peer reviewers.

Supplementary materials


References


[41] Anna Panfilova, Olesna Nemchenko, Liussine Simonian, Oksana Tsurikova. The analysis of organizational approaches in drug registration in the EU.